Hims & Hers is expanding its offerings through the Trybe Labs deal after it added compounded weight loss drugs.

We believe there is minimal cause for concern with HIMS stock, which makes it attractive but highly sensitive to adverse events as its current valuation is extremely ...

Hims & Hers Health, Inc. is a dramatically undervalued company if your holding period can be measured in decades. Read more ...

Raising its price target on the shares to $21, reports The Fly, BofA nonetheless reiterated an "underperform" ( i.e., sell) ...

Hims & Hers, a health and wellness platform, is set to introduce at-home lab testing capabilities through the acquisition of ...

Telehealth pioneer Hims & Hers Health (HIMS) stock is soaring, with a 12% gain in recent days and a whopping 176% in the last ...

Hims & Hers' acquisition of Trybe Labs broadens its treatment range and enhances its competitive edge through increased data ...

Hims & Hers Health Inc is a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals, ...

Shares of Hims & Hers Health Inc (NYSE: HIMS) are flying higher on Wednesday. The gain comes as the S&P 500 gained 0.1%, and ...

Hims & Hers Health Inc (NYSE:HIMS) shares are soaring Wednesday after the company announced plans to introduce at-home lab ...

By acquiring Sigmund NJ LLC, known as Trybe Labs, Hims & Hers will be able "to support at-home blood draws and more ...

Hims & Hers Health, Inc. (NYSE:HIMS – Get Free Report)’s share price hit a new 52-week high during trading on Wednesday after Bank of America raised their price target on the stock from $18.00 to $21.